Benzinga | Nov 2, 2021 10:54AM EDT

Histogen And Amerimmune Announce The Presentation Of Emricasan Data In COVID-19 At The American College Of Allergy, Asthma, And Immunology Conference

Histogen Inc. (NASDAQ:HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function and its partner, Amerimmune, LLC, today announced that Amerimmune's CEO, Oral Alpan, MD, will present updated findings from the emricasan Phase 1 study in mild symptomatic COVID-19 patients at the American College of Allergy, Asthma, and Immunology Conference in New Orleans on November 6, 2021. The presentation details are as follows:

EVENT: American College of Allergy, Asthma, and Immunology

DATE: November 6, 2021

TITLE: Role of Cellular Caspases and Therapeutic Potential of a Pan-Caspase Inhibitor, Emricasan, in COVID-19

"The Phase 1 trial showed excellent safety in early-stage, mildly symptomatic COVID-19 patients in a small cohort of individuals that received orally-dosed emricasan. Emricasan shortened clinical symptoms and quickened recovery from COVID-19 when compared to placebo group. In addition, the original discovery made by Amerimmune on disease-related biomarkers, including elevated caspase levels, enabled us to focus on understanding how the virus affects the immune system, as opposed to how the body reacts to the coronavirus infection. Most of the current approaches to treating COVID-19 focus on how the body is reacting after the infection. Our approach, with emricasan, is to target the infection with a proactive treatment that prevents an overactive immune system that leads to uncontrolled inflammation and severe symptoms," said Oral Alpan, MD, CEO of Amerimmune LLC.

"We are pleased that the positive findings from our emricasan clinical program targeting mild symptomatic COVID-19 patients have been accepted for an oral presentation at this prestigious medical conference and we look forward to supporting our partner Amerimmune as they seek to advance emricasan in the clinic through one or more partnerships," said Richard W. Pascoe, CEO of Histogen.